Ser84

Site Information
sPARtPPsEEDSAEA SwissProt Entrez-Gene
Blast this site against: NCBI SwissProt PDB
Site Group ID: 3175404
Available spectra: 1 CST

In vivo Characterization
Methods used to characterize site in vivo:	mass spectrometry ( 1 , 2 , 3 , 4 , 5 , 6 , 7 , 9 , 10 , 11 )
Disease tissue studied:	breast cancer ( 1 ) , lung cancer ( 3 , 4 , 5 , 6 , 7 ) , non-small cell lung cancer ( 4 , 5 , 6 , 7 ) , non-small cell lung adenocarcinoma ( 4 , 5 , 6 ) , non-small cell large cell lung carcinoma ( 4 ) , small-cell lung cancer ( 3 ) , melanoma skin cancer ( 2 , 11 )
Relevant cell line - cell type - tissue:	BT-474 (breast cell) ( 1 ) , Cal-12T (pulmonary) ( 6 ) , Calu 6 (pulmonary) ( 7 ) , DMS153 (pulmonary) ( 5 ) , DMS79 (pulmonary) ( 3 ) , H2009 (pulmonary) ( 7 ) , H2077 (pulmonary) ( 7 ) , H2887 (pulmonary) ( 7 ) , H322M (pulmonary) ( 7 ) , HCC44 (pulmonary) ( 6 ) , HCC827 (pulmonary) ( 7 ) , HeLa (cervical) ( 9 , 10 ) , LCLC-103H (pulmonary) ( 7 ) , lung ( 3 , 4 , 5 , 6 ) , MCF-7 (breast cell) ( 1 ) , NCI-H128 (pulmonary) ( 3 ) , NCI-H1299 (pulmonary) ( 4 ) , NCI-H1417 (pulmonary) ( 3 ) , NCI-H1437 (pulmonary) ( 5 , 6 ) , NCI-H1648 (pulmonary) ( 7 ) , NCI-H1666 (pulmonary) ( 6 ) , NCI-H1734 (pulmonary) ( 4 ) , NCI-H1944 (pulmonary) ( 4 ) , NCI-H2073 (pulmonary) ( 5 ) , NCI-H209 (pulmonary) ( 3 , 5 ) , NCI-H2405 (pulmonary) ( 6 ) , NCI-H358 (pulmonary) ( 4 ) , NCI-H460 (pulmonary) ( 4 ) , NCI-H520 (squamous) ( 7 ) , NCI-H524 (pulmonary) ( 3 ) , NCI-H838 (pulmonary) ( 5 ) , PC9 (pulmonary) ( 7 ) , skin ( 11 ) , WM239A (melanocyte) ( 2 )

References
1	Carrier M, et al. (2016) Phosphoproteome and Transcriptome of RA-Responsive and RA-Resistant Breast Cancer Cell Lines. PLoS One 11, e0157290 27362937 Curated Info
2	Stuart SA, et al. (2015) A Phosphoproteomic Comparison of B-RAFV600E and MKK1/2 Inhibitors in Melanoma Cells. Mol Cell Proteomics 14, 1599-615 25850435 Curated Info
3	Rikova K, Hall B (2013) CST Curation Set: 20734, 21161, 30112, 30153, 30154; Year: 2013; Biosample/Treatment: cell line, H1417, DMS79, H128, H209, H524; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY, p[ST], RXXp[ST], pSQ, p[ST]QG, LXRXXp[ST], p[ST]P Curated Info
4	Rikova K, Hall B (2013) CST Curation Set: 20737, 21164, 30161, 30162, 30163; Year: 2013; Biosample/Treatment: cell line, H1299, H1944, H358, H1734, H460; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY, p[ST], RXXp[ST], pSQ, p[ST]QG, LXRXXp[ST], p[ST]P Curated Info
5	Rikova K, Hall B (2013) CST Curation Set: 20742, 21169, 30176, 30177, 30178; Year: 2013; Biosample/Treatment: cell line, H838, DMS153, H2073, H209, H1437; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY, p[ST], RXXp[ST], pSQ, p[ST]QG, LXRXXp[ST], p[ST]P Curated Info
6	Rikova K, Hall B (2013) CST Curation Set: 20741, 21168, 30173, 30174, 30175; Year: 2013; Biosample/Treatment: cell line, H1666, CAL-12T, H2405, HCC44, H1437; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY, p[ST], RXXp[ST], pSQ, p[ST]QG, LXRXXp[ST], p[ST]P Curated Info
7	Klammer M, et al. (2012) Phosphosignature predicts dasatinib response in non-small cell lung cancer. Mol Cell Proteomics 11, 651-68 22617229 Curated Info
8	Beli P, et al. (2012) Proteomic Investigations Reveal a Role for RNA Processing Factor THRAP3 in the DNA Damage Response. Mol Cell 46, 212-25 22424773 Curated Info
9	Zhou J (2010) CST Curation Set: 10689; Year: 2010; Biosample/Treatment: cell line, HeLa/nocodazole; Disease: cervical adenocarcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]P Antibodies Used to Purify Peptides prior to LCMS: Phospho-Thr-Pro Motif Antibody (polyAB) Cat#: 3003, PTMScan(R) Phospho-Thr-Pro Motif (T*P) Immunoaffinity Beads Cat#: 1996 Curated Info
10	Zhou J (2010) CST Curation Set: 10686; Year: 2010; Biosample/Treatment: cell line, HeLa/untreated; Disease: cervical adenocarcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]P Antibodies Used to Purify Peptides prior to LCMS: Phospho-Thr-Pro Motif Antibody (polyAB) Cat#: 3003, PTMScan(R) Phospho-Thr-Pro Motif (T*P) Immunoaffinity Beads Cat#: 1996 Curated Info
11	Tucker M (2010) CST Curation Set: 9779; Year: 2010; Biosample/Treatment: tissue, skin/untreated; Disease: melanoma skin cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]P Curated Info